• ATRIVA Therapeutics

    First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including influenza and potentially coronaviruses.


    Great potential against influenza virus due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002.

    Phase I clinical trial successfully completed, Phase II in influenza under preparation.


    Learn more


  • ATRIVA Therapeutics

    Invest in research to contribute to pandemic preparedness!


    We invite you to explore our approach and development milestones presented on this website and encourage you to contact us directly.


    Get in touch


  • 1
  • 2
  • First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including influenza and potentially coronaviruses.

    Learn more
  • Invest in research to contribute to pandemic preparedness!

    Get in touch
  • 1
  • 2

About Us

Learn more about the team behind ATRIVA Therapeutics GmbH.

 

Read more

The ATRIVA Approach

Novel host-targeting approach to prevent viral replication.

 

Read more

    Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week

    Tübingen (Germany), January 8, 2020 – Atriva Therapeutics GmbH, a clinical stage biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announces its participation in three upcoming conferences in San Francisco, CA, USA, in January. Dr. Rainer Lichtenberger, CEO, Dr. Christian Wallasch, COO, and Dr. Björn Cochlovius, VP Business Development, will represent the Company and be available for networking and one-on-one meetings at the following events:

    Biotech ShowcaseTM

    January 13th – 15th, 2020, Hilton San Francisco Union Square, San Francisco

    Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation on Jan. 13th, at 11:30 am, in room Franciscan D (Ballroom Level).

    https://informaconnect.com/biotech-showcase/

    RESI, Redefining Early Stage Investments

    January 14th, 2020, Marines’ Memorial Club & Hotel, San Francisco

    Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation at 8:00 am, during the Track 4, Biotech Entrepreneur Pitch Session.

    https://www.resiconference.com/

    15th Non-Dilutive Funding Summit

    January 15th, 2020, Marines’ Memorial Club & Hotel, San Francisco

    https://www.freemindconsultants.com/15th-annual-non-dilutive-funding-summit-2/

    About Atriva Therapeutics GmbH

    Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop new antiviral therapies against different severe respiratory viral infections. Atriva’s lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. The Company owns nine broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2039. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

    For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.

    Contact:

    Atriva Therapeutics GmbH
    Dr. Rainer Lichtenberger, CEO
    phone: +49 7071 859 7673

    mobile: +49 173 743 1897
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Media and Investor Relations:

    MC Services AG

    Raimund Gabriel / Eva Bauer

    phone: +49 89 21022880

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Latest News

    Contact Form

    Please, enter your name
    Please, enter your phone number
    Please, enter your e-mail address Mail address is not not valid
    Please, enter your message

    Address

    Atriva Therapeutics GmbH
    Christophstr. 32, 72072 Tübingen

    +49 (0)7071 8597673
    info@atriva-therapeutics.com

    LinkedIn
    Twitter

    In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.